{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-003117","form_type":"8-K","ticker":"CHRS","cik":"0001512762","company_name":"Coherus Oncology, Inc.","filed_at":"2026-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.277431+00:00","generated_at":"2026-05-16T10:39:21.978571+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"low","headline":"Coherus Oncology provides preliminary FY2025 revenue and cash at J.P. Morgan conference","bullets":["Filing furnishes preliminary unaudited net revenues for Q4 and FY2025 ended Dec 31, 2025.","Preliminary cash, cash equivalents and investments as of Dec 31, 2025 also disclosed.","Slide includes forward-looking projection of LOQTORZI revenue growth.","Actual final results may differ materially; independent auditor has not reviewed these preliminary figures."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-003117","json":"https://secwatch.observer/filing/0001104659-26-003117.json","markdown":"https://secwatch.observer/filing/0001104659-26-003117.md","text":"https://secwatch.observer/filing/0001104659-26-003117.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1512762/000110465926003117/0001104659-26-003117-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1512762/000110465926003117/chrs-20260113x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:39:21.978571+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}